發(fā)布時間：2018-11-09 18:00

【摘要】：目的：探討慢性阻塞性肺疾病患者規(guī)律使用噻托溴銨粉吸入劑1年后，在臨床癥狀、肺功能、急性加重風險等，在各組的變化情況。 方法：本試驗采用病例對照研究。依照中華醫(yī)學會制定的COPD相關(guān)診斷標準診斷為慢性阻塞性肺疾病的64例患者，分為使用噻托溴銨粉吸入劑治療的噻托溴銨組和常規(guī)治療未使用噻托溴銨患者的對照組。按2011年GOLD全球策略的病情嚴重程度評估標準，分為A、B、C、D組，每組取8人入組噻托溴銨組。1年后評估兩組及各項對應分組間患者，，在呼吸困難指數(shù)、肺功能、急性加重次數(shù)方面的變化情況。 結(jié)果：兩組患者及各項對應分組間，入組時在性別、年齡、呼吸困難指數(shù)、肺功能及過去1年急性加重次數(shù)等均無統(tǒng)計學差異。1年后評估，發(fā)現(xiàn)噻托溴銨組患者呼吸困難指數(shù)有明顯下降(P0.05)、年急性加重次數(shù)明顯減少(P0.05)，但肺功能也有明顯下降(P0.05)；對照組患者呼吸困難指數(shù)沒有差異，年急性加重次數(shù)也沒有變化，而肺功能下降明顯（P0.001）。提示噻托溴銨粉吸入劑能改善慢阻肺的臨床癥狀和年急性加重次數(shù)。分析噻托溴銨組和對照組肺功能的差異時發(fā)現(xiàn)噻托溴銨組肺功能下降程度明顯低于對照組(P0.05)，說明噻托溴銨粉吸入劑能延緩慢阻肺患者肺功能下降。在A、B、C、D相應組間分析上，發(fā)現(xiàn)A組間呼吸困難指數(shù)、年急性加重次數(shù)無差別，但肺功能下降程度噻托溴銨組低于對照組(P0.05)；B組間呼吸困難指數(shù)噻托溴銨組低于對照組(P0.05)，肺功能下降程度噻托溴銨組低于對照組(P0.05)，但年急性加重次數(shù)無差別。C組間噻托溴銨組年急性加重次數(shù)明顯低于對照組(P0.05)，肺功能下降程度也低于對照組(P0.05)，但呼吸困難指數(shù)兩組間無差別。D組間噻托溴銨組呼吸困難指數(shù)低于對照組(P0.05)，年急性加重次數(shù)少于對照組(P0.05)，但肺功能下降程度兩者間沒有差異。提示噻托溴銨能延緩A組、B組、C組患者的肺功能下降速度，而對D組沒有作用。噻托溴銨能減少B組、D組的年急性加重次數(shù)，改善B組、D組的呼吸困難癥狀。 結(jié)論：噻托溴銨粉可以延緩肺功能下降的速度，改善呼吸困難指數(shù)、減少急性加重次數(shù)。 噻托溴銨能延緩A組、B組、C組患者的肺功能下降速度，減少B組、D組的年急性加重次數(shù)，改善B組、D組的呼吸困難癥狀。
[Abstract]:Objective: to investigate the changes of clinical symptoms, pulmonary function, acute exacerbation risk and so on in patients with chronic obstructive pulmonary disease (COPD) after regular use of tiotropium bromide powder inhalation for one year. Methods: a case-control study was conducted. Sixty-four patients with chronic obstructive pulmonary disease (COPD) were divided into two groups: tiotropium group treated with tiotropium powder inhalation and control group with routine treatment without tiotropium bromide according to the COPD diagnostic criteria established by the Chinese Medical Association. According to the criteria for evaluating the severity of GOLD's global strategy in 2011, the patients were divided into two groups: group A (n = 8) and group D (n = 8). One year later, patients in two groups and their corresponding groups were evaluated for dyspnea index and pulmonary function. Changes in the number of acute exacerbations. Results: there were no significant differences in sex, age, dyspnea index, pulmonary function and acute exacerbation in the past year between the two groups. It was found that the dyspnea index of patients in tiotropium group was significantly decreased (P0.05), the number of acute exacerbations was significantly decreased (P0.05), but the pulmonary function was also significantly decreased (P0.05). There was no difference in dyspnea index and the number of acute exacerbations in the control group, but the pulmonary function decreased significantly (P0.001). The results suggest that tiotropium bromide powder inhalation can improve the clinical symptoms and acute exacerbation times of COPD. After analyzing the difference of pulmonary function between tiotropium group and control group, it was found that the decrease of pulmonary function in tiotropium group was significantly lower than that in control group (P0.05), which indicated that tiotropium powder inhalation could delay the decline of pulmonary function in patients with chronic obstructive pulmonary disease. There was no significant difference in dyspnea index and acute exacerbation between group A and group A, but the degree of pulmonary function decline was lower in tiotropium group than that in control group (P0.05). The index of dyspnea in group B was lower than that in control group (P0.05), and the degree of pulmonary function decline in group B was lower than that in group B (P0.05). The number of acute exacerbations in group C was significantly lower than that in control group (P0.05), and the degree of pulmonary function decline was also lower than that in control group (P0.05). But there was no difference in dyspnea index between two groups. The dyspnea index of group D was lower than that of control group (P0.05), the number of acute exacerbation was less than that of control group (P0.05), but there was no difference between the two groups in the degree of pulmonary function decline. It suggested that tiotropium bromide could delay the decline of pulmonary function in group A, group B and group C, but had no effect on group D. Tiotropium bromide decreased the number of acute exacerbations in group B and D, and improved dyspnea in group B and D. Conclusion: tiotropium bromide powder can delay the decline of pulmonary function, improve the index of dyspnea and decrease the times of acute exacerbation. Tiotropium bromide could delay the decline of pulmonary function in group A, group B and group C, decrease the number of acute exacerbations in group B and group D, and improve the symptoms of dyspnea in group B and group D.
【學位授予單位】：大連醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2013
【分類號】：R563.9

【參考文獻】

相關(guān)期刊論文 前4條

1 王久伶;聶秀紅;魏兵;肖漢;任魁;;BODE評分和FEV1對慢性阻塞性肺疾病患者運動能力評價的比較[J];北京醫(yī)學;2007年08期

2 張婧;;慢性阻塞性肺疾病中BODE指數(shù)的應用進展[J];臨床肺科雜志;2011年02期

3 柳濤;蔡柏薔;;慢性阻塞性肺疾病診斷、處理和預防全球策略(2011年修訂版)介紹[J];中國呼吸與危重監(jiān)護雜志;2012年01期

4 蔡柏薔,張弘;慢性阻塞性肺疾病患者病情和治療療效的評估[J];中華結(jié)核和呼吸雜志;2005年07期

本文編號：2321153